PTCT vs. MRVI, GLPG, NAMS, GERN, KROS, AMPH, RNA, SDGR, AGIO, and SNDX
Should you be buying PTC Therapeutics stock or one of its competitors? The main competitors of PTC Therapeutics include Maravai LifeSciences (MRVI), Galapagos (GLPG), NewAmsterdam Pharma (NAMS), Geron (GERN), Keros Therapeutics (KROS), Amphastar Pharmaceuticals (AMPH), Avidity Biosciences (RNA), Schrödinger (SDGR), Agios Pharmaceuticals (AGIO), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical preparations" industry.
PTC Therapeutics (NASDAQ:PTCT) and Maravai LifeSciences (NASDAQ:MRVI) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, community ranking, profitability, media sentiment and institutional ownership.
50.3% of Maravai LifeSciences shares are owned by institutional investors. 5.3% of PTC Therapeutics shares are owned by company insiders. Comparatively, 0.2% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Maravai LifeSciences has a net margin of -41.19% compared to PTC Therapeutics' net margin of -62.45%. PTC Therapeutics' return on equity of 0.00% beat Maravai LifeSciences' return on equity.
In the previous week, PTC Therapeutics had 16 more articles in the media than Maravai LifeSciences. MarketBeat recorded 18 mentions for PTC Therapeutics and 2 mentions for Maravai LifeSciences. PTC Therapeutics' average media sentiment score of 0.99 beat Maravai LifeSciences' score of -0.20 indicating that PTC Therapeutics is being referred to more favorably in the media.
PTC Therapeutics received 482 more outperform votes than Maravai LifeSciences when rated by MarketBeat users. However, 67.06% of users gave Maravai LifeSciences an outperform vote while only 62.03% of users gave PTC Therapeutics an outperform vote.
PTC Therapeutics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500.
PTC Therapeutics currently has a consensus price target of $33.67, suggesting a potential upside of 4.75%. Maravai LifeSciences has a consensus price target of $11.56, suggesting a potential upside of 47.20%. Given Maravai LifeSciences' stronger consensus rating and higher possible upside, analysts plainly believe Maravai LifeSciences is more favorable than PTC Therapeutics.
Maravai LifeSciences has lower revenue, but higher earnings than PTC Therapeutics. Maravai LifeSciences is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Maravai LifeSciences beats PTC Therapeutics on 10 of the 18 factors compared between the two stocks.
Get PTC Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PTCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PTC Therapeutics Competitors List
Related Companies and Tools
